Zhigang Wang, MSc, PharmD

Katholieke Universiteit Leuven, Belgium

Poster(s):

• P2544 - Model-Informed Dosing Interval Extension of Infliximab in Patients With Inflammatory Bowel Diseases: Six Months Interim Analysis of the MODIFI Trial
  Monday, October 28, 2024

  10:30 AM – 4:00 PM ET

• P2545 - Fecal Calprotectin Decreases Following Transition to Subcutaneous CT-P13 in Patients With Inflammatory Bowel Diseases on Escalated Intravenous Infliximab Maintenance Therapy
  Monday, October 28, 2024

  10:30 AM – 4:00 PM ET